Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  GenMark Diagnostics, Inc    GNMK

GENMARK DIAGNOSTICS, INC (GNMK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Glancy Prongay & Murray LLP : Continues Investigation on Behalf of GenMark Diagnostics, Inc. Investors (GNMK)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:31pm CEST

Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of GenMark Diagnostics, Inc. (“GenMark” or the “Company”) (NASDAQ: GNMK) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the GenMark investigation page on our website www.glancylaw.com/case/genmark-diagnostics-inc.

On November 2, 2017, GenMark disclosed that the administrative approval process for ePlex in Europe was taking significantly longer than expected—in some cases in excess of 180 days—which was affecting revenue generation.

On this news, GenMark’s share price fell $3.00 or approximately 41%, to close at $4.26 per share on November 3, 2017, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased GenMark securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENMARK DIAGNOSTICS, INC
10/15GENMARK DIAGNOSTICS : Schedules Third Quarter Financial Results Conference Call ..
AQ
10/04GENMARK DIAGNOSTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
10/04GENMARK DIAGNOSTICS, INC. : Entry into a Material Definitive Agreement (form 8-K..
AQ
10/03GENMARK DIAGNOSTICS : Announces FDA Submission of its ePlex Blood Culture Identi..
AQ
10/02GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Ident..
GL
08/02GENMARK DIAGNOSTICS, INC. : Amendments to Articles of Inc. or Bylaws; Change in ..
AQ
07/31GENMARK DIAGNOSTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
07/30GENMARK DIAGNOSTICS : 2Q Earnings Snapshot
AQ
07/30GENMARK DIAGNOSTICS, INC. : Results of Operations and Financial Condition (form ..
AQ
07/30GenMark Diagnostics Reports Second Quarter 2018 Results
GL
More news
News from SeekingAlpha
10/02Genmark submits two new ePlex panels for FDA clearance 
09/14Canaccord bullish on medical diagnostic firms 
07/30GenMark Diagnostics, Inc. (GNMK) CEO Hany Massarany on Q2 2018 Results - Earn.. 
07/30GenMark Diagnostics misses by $0.08, beats on revenue 
07/27Med tech stocks mired in the red following Edwards, Mettler-Toledo results 
Financials ($)
Sales 2018 71,0 M
EBIT 2018 -44,6 M
Net income 2018 -47,9 M
Debt 2018 16,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,05x
EV / Sales 2019 3,88x
Capitalization 342 M
Chart GENMARK DIAGNOSTICS, INC
Duration : Period :
GenMark Diagnostics, Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMARK DIAGNOSTICS, INC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 10,5 $
Spread / Average Target 72%
EPS Revisions
Managers
NameTitle
Hany Massarany President, Chief Executive Officer & Director
James Charles Fox Chairman
Brian Mitchell Senior Vice President-Operations
Scott Mendel CFO & Principal Accounting Office
Daryl Jay Faulkner Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GENMARK DIAGNOSTICS, INC46.52%342
THERMO FISHER SCIENTIFIC21.87%93 211
DANAHER CORPORATION9.88%72 341
INTUITIVE SURGICAL42.29%60 516
BOSTON SCIENTIFIC CORPORATION46.95%51 154
ILLUMINA47.23%47 288